Tracks: Interventional Hypertension (Non-CME)
David Kandzari, MD, FACC, FSCAI
Director, Interventional Cardiology, Piedmont Heart Institute; Chief Scientific Officer, Piedmont Healthcare
Piedmont Heart Institute
Atlanta, Georgia, United States
Disclosure(s): Medtronic: Advisor (Ongoing), Clinical Trial Investigator (Ongoing), Clinical Trial Support (Ongoing), Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing)
Felix Mahfoud, MD
Professor
Saarland University Hospital
Homburg/Saar, Saarland, Germany
No relationships to disclose
Vasilios Papademetriou, MD, DSc
Director Interventional Hypertension and Vascular Medicine
Georgetown University/VAMC
Washington, District of Columbia, United States
No relationships to disclose
Andrew Sharp, MD
Consultant Cardiologist
University Hospital of Wales
Cardiff, United Kingdom
Disclosure(s): Boston Scientific: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Penumbra: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Philips: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Recor Medical: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)